RightFit
RecruitingPhase 1

A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.

A Phase 1/1b First-in-human Study of BMS-986463 in Advanced Malignant Tumors

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years and older
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study tests increasing doses of BMS-986463 in people with certain advanced cancers. It looks at how safe the drug is, how well people handle it, and how well it works.

The purpose of this study is to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with select advanced malignant tumors.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • You must be fully active or able to do light work, even if hard physical activity is limited.
  • You must have a tumor spot that can be biopsied, separate from the spot used to track treatment. A fresh tissue sample must be taken before treatment.
  • You must have carcinoma, a type of cancer, that cannot be removed by surgery or has spread to other parts of the body.

Who can't join

  • You cannot have cancer that has spread to the thin layers covering the brain and spinal cord.
  • You cannot have another cancer that needs treatment during screening, or a past cancer that was active in the 2 years before treatment.
  • You cannot have had radiation treatment within 2 weeks before starting study treatment.
  • Other study rules also apply.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria * Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1. * Participants must have at least 1 lesion accessible for biopsy in addition to the target lesion, from which a fresh pre treatment biopsy must be obtained. * Participants must have an unresectable/metastatic carcinoma. Exclusion Criteria * Participants must not have Leptomeningeal metastases. * Participants must not have concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to treatment. * Participants must not have had any prior radiation therapy within 2 weeks prior to start of study treatment. * Other protocol-defined Inclusion/Exclusion criteria apply.

Study sites (6)

CA

NJ

OH

TX